Evidence map›Paper›PMID 31181284›Full record

ReviewAntiviral research2019

The development and approval of tecoviromat (TPOXX

Michael Merchlinsky, Andrew Albright, Victoria Olson, Helen Schiltz, Tyler Merkeley, Claiborne Hughes, Brett Petersen, Mark Challberg

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Antiviral research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05597735 (A Phase III, Multi-country, Randomized, Placebo-controlled, Double-blinded Trial to Assess the Efficacy and Safety of Tecovirimat Antiviral Treatment for Patients With Monkeypox Virus Disease), which is not on this map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05597735 phase3active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase III, Multi-country, Randomized, Placebo-controlled, Double-blinded Trial to Assess the Efficacy and Safety of Tecovirimat Antiviral Treatment for Patients With Monkeypox Virus Disease

TypeinterventionalSponsorANRS, Emerging Infectious DiseasesRan2023 to 2026Enrolled480ConditionsMonkeypox, MpoxArmsTecovirimat, Placebo
3 · Its place in the literature

Who cites it

68 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. From neglected to notoriety: a review of Mpox clinical features, virology, epidemiology, treatment and prevention strategies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michael MerchlinskyBiomedical Advanced Research and Development Authority, 300 C Street SW, Washington DC, 20201, USA. Electronic address: Michael.merchlinsky@hhs.gov.
Andrew AlbrightBiomedical Advanced Research and Development Authority, 300 C Street SW, Washington DC, 20201, USA.
Victoria OlsonNational Center for Emerging and Zoonotic Infectious Disease, Centers for Disease Control and Prevention, Mail Stop G-06, 1600 Clifton Road, NE, Atlanta, 30333, Georgia.
Helen SchiltzNational Institute of Allergy and Infectious Diseases, National Institutes of Health, MSC 9825, 5601 Fishers Lane, Rockville, MD, 20851, USA.
Tyler MerkeleyBiomedical Advanced Research and Development Authority, 300 C Street SW, Washington DC, 20201, USA.
Claiborne HughesBiomedical Advanced Research and Development Authority, 300 C Street SW, Washington DC, 20201, USA.
Brett PetersenNational Center for Emerging and Zoonotic Infectious Disease, Centers for Disease Control and Prevention, Mail Stop G-06, 1600 Clifton Road, NE, Atlanta, 30333, Georgia.
Mark ChallbergNational Institute of Allergy and Infectious Diseases, National Institutes of Health, MSC 9825, 5601 Fishers Lane, Rockville, MD, 20851, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

The classification of smallpox by the U.S. Centers for Disease Control and Prevention (CDC) as a Category A Bioterrorism threat agent has resulted in the U.S. Government investing significant funds to develop and stockpile a suite of medical countermeasures to ameliorate the consequences of a smallpox epidemic. This stockpile includes both vaccines for prophylaxis and antivirals to treat symptomatic patients. In this manuscript, we describe the path to approval for the first therapeutic against smallpox, identified during its development as ST-246, now known as tecovirimat and TPOXX

Indexed as

Drug DevelopmentAnimalsAntiviral AgentsBenzamidesDisease Models, AnimalDrug Evaluation, PreclinicalHumansIsoindolesPhthalimidesSmallpoxUnited StatesUnited States Food and Drug AdministrationVariola virusAntiviral AgentsBenzamidesIsoindolesPhthalimidestecovirimatAntiviral therapyFDA animal ruleSmallpoxTecovirimatVariola virus

Identifiers

PMID31181284
PMCPMC6663070

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.